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Objectives. This study sought to document the safety of dobut-
amine stress echocardiography as it has evolved at a single center
and to define predictors of adverse events.
Background. The indications and protocol for dobutamine
stress testing have evolved over 5 years of clinical use, but the
influence of these changes on the safety and side effects of the test
is undefined.
Methods. Over 5 years, 3,011 consecutive dobutamine stress
studies were performed in 2,871 patients, using an incremental
protocol from 5 to 40 mg/kg body weight per min in 3-min stages,
followed by atropine or an additional stage with 50 mg/kg per min,
if required. Clinical data were gathered prospectively, and hemo-
dynamic and echocardiographic findings were recorded at each
stage, including recovery. Dobutamine echocardiography was de-
fined as positive for ischemia in the presence of new or worsening
wall motion abnormalities; in the absence of ischemia, failure to
attain 85% of age-predicted maximal heart rate was identified as
a nondiagnostic result.
Results. Studies were performed for risk assessment (70%) and
symptom evaluation (30%); over the study period, there was an
increment in the use of dobutamine echocardiography for preop-
erative evaluation. Most tests (n 5 2,194 [73%]) were terminated
due to attainment of peak dose with achievement of target heart
rate (>85% maximal age-predicted heart rate); 455 patients
(15%) failed to achieve >85% maximal predicted heart rate
despite maximal doses of dobutamine and atropine. The protocol
was stopped prematurely in 230 patients (7.6%) because of side
effects, including ventricular (n 5 27 [0.9%]) and supraventricu-
lar rhythm disorders (n 5 22 [0.7%]), severe hypertension (n 5 24
[0.8%]) and hypotension or left ventricular outflow tract obstruc-
tion (n 5 112 [3.8%]). Noncardiac symptoms, such as headache,
nausea or anxiety, caused early test termination in 45 patients
(1.6%). The remaining tests were stopped because of severe chest
pain (n 5 106 [3.5%]) or severe ischemia by echocardiography
(n 5 26 [0.9%]). Serious complications occurred in nine patients,
including sustained ventricular tachycardia in five, myocardial
infarction in one and other conditions in three requiring hospital
admission (sustained supraventricular tachycardia, hypotension,
suspected myocardial infarction), but neither ventricular fibrilla-
tion nor death occurred. Independent predictors of serious com-
plications could not be defined. Over 5 years, higher dose proto-
cols and more frequent use of atropine have raised the number of
diagnostic protocols from 59% to 80%, without increasing the
incidence of major side effects.
Conclusions. Despite the use of more aggressive protocols and
alterations of the indications for testing to include sicker patients,
major side effects are a rare complication of dobutamine echocar-
diography.
(J Am Coll Cardiol 1997;29:1234–40)
©1997 by the American College of Cardiology
Since the first reported use of dobutamine as a cardiac stress
agent in 1984, this synthetic catecholamine has become in-
creasingly important in pharmacologic stress testing. Initially
used as a test for the diagnosis of coronary artery disease in
patients unable to exercise (1,2), the indications for dobut-
amine echocardiography have expanded into risk stratification
of patients undergoing vascular surgery (3–6), patients with
stable chronic coronary disease (7) or previous myocardial
infarction (8,9), as well as the assessment of myocardial
viability (10–13). Thus, the test has been applied to progres-
sively more complex, older and higher risk patients as it has
been shown to be of prognostic value.
In the context of expanding the indications to include sicker
patients and the use of increasingly aggressive protocols,
including combination with atropine (14,15), the results of
older studies of safety and efficacy may be less applicable
(16,17). The only recent study of the safety of dobutamine
echocardiography, involving ;2,800 patients at overseas cen-
ters, identified serious side effects in 0.5% but enrolled patients
generally younger than those usually requiring a pharmaco-
logic stress study in the United States (18). Importantly, that
study did not enroll patients undergoing perioperative risk
stratification, a group that comprises patients with serious
comorbidity, including elderly patients undergoing vascular
and orthopedic surgery, those with end-stage renal disease and
patients with severe chronic left ventricular dysfunction. Thus,
the purpose of the present study was to document the safety
and side effects of dobutamine echocardiography over a period
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of 5 years at a single large center. An attempt was made to
define predictors of adverse events and show trends in their
frequency, in parallel with changes in the dobutamine echo-
cardiographic protocol and indications.
Methods
Study population. Between July 1991 and December 1995,
3,011 consecutive dobutamine echocardiograms were acquired
in 2,871 patients (mean [6SD] age 66 6 12 years, range 19 to
94; 1,688 men [56%]) at our institution. Clinical and hemody-
namic data were collected prospectively. Table 1 summarizes
the changes in the clinical profile of the study patients.
Diabetes mellitus was present in 560 patients (19%), with an
increasing prevalence of patients with this diagnosis, and
comparable numbers of insulin-dependent (n 5 286) and
non–insulin-dependent (n 5 274) diabetic patients. Many
patients had known coronary artery disease, including previous
myocardial infarction (n 5 476), previous coronary artery
bypass graft surgery (n 5 417) or coronary angioplasty (n 5
241) or were receiving medical therapy, including beta-
adrenergic blocking agents (n 5 585), angiotensin-converting
enzyme inhibitors (n 5 636) and diuretic drugs (n 5 981).
Dobutamine–atropine infusion protocol. Patients were re-
quested to discontinue beta-blockers on the day of the stress
test, but other antianginal therapy was not routinely stopped.
Before starting the infusion, hemodynamic variables were
assessed at rest, and a 12-lead electrocardiogram (ECG) and
two-dimensional echocardiogram were also obtained at rest.
Dobutamine was then infused, starting at a dose of 5 mg/kg
body weight per min, increasing to 10, 20, 30 and 40 mg/kg per
min at intervals of 3 min. If ,85% maximal age-predicted
heart rate was achieved at the end of the standard protocol,
and in the absence of contraindications, such as glaucoma or
symptoms of prostatic obstruction, atropine (in 0.25-mg bo-
luses to 2 mg) was administered (14) or an additional stage
with 50 mg/kg per min of dobutamine was added, or both. The
infusion was terminated after the maximal dose of dobutamine
was administered or the target heart rate was achieved (end of
protocol), or if one of the following developed: severe angina,
severe left ventricular outflow tract obstruction (Doppler
gradient .65 mm Hg with systolic anterior motion of the
mitral valve) or other major side effects (systolic blood pres-
sure decrease .20 mm Hg below baseline and ,100 mm Hg,
persistent systolic blood pressure increase .220 mm Hg,
severe rhythm disorders, severe vagal reaction or other intol-
erable noncardiac symptoms, including headache or nausea).
The target heart rate was used as an end point before
attainment of a peak dose ,40 mg/kg per min in 321 tests
(11%), more commonly in the initial part of this experience.
ECG and echocardiographic imaging. A 12-lead ECG and
hemodynamic variables were continuously monitored through-
out the infusion and at least 6 min into recovery. Clinical
evidence of ischemia was identified if the patients developed
anginal pain or ST segment changes.
Echocardiographic images in the parasternal long- and
short-axis and two- and four-chamber views were obtained at
rest and at each stage of the test, as well as during recovery
(usually 3 min after the end of the infusion). Images at rest, low
dose (10 mg/kg per min), prepeak (30 mg/kg per min) and peak
dose were digitized and displayed in a quad-screen digital
format. Studies were interpreted by at least two observers who
had no knowledge of the clinical and ECG data. Regional wall
motion scores were obtained at each stage and graded as
normal, mild or severely hypokinetic, akinetic or dyskinetic,
using a 16-segment model (19). Echocardiographic evidence of
ischemia was identified if regional function worsened in any
segment, except if the basal inferior or septal walls were
involved, in which case an adjacent abnormal segment was
required (20). Studies were identified as nondiagnostic if the
patient attained ,85% age-predicted maximal heart rate in the
absence of inducible ischemia. Interpretation was attempted in
all patients, and although in five the test was nondiagnostic due
to poor image quality, no study was terminated for this reason.
Statistical analysis. Continuous variables are reported as
mean value 6 SD and range and compared using analysis of
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ECG 5 electrocardiogram, electrocardiographic






(n 5 1,239) p Value
Age (yr) 64 6 12 66 6 12 66 6 12 0.0005
Male 496 (57%) 510 (57%) 682 (55%) 0.62
Diabetes mellitus 143 (17%) 136 (15%) 281 (23%) , 0.0001
End-stage renal disease 58 (7%) 59 (7%) 133 (11%) , 0.0001
Atherosclerotic vascular disease 205 (24%) 273 (30%) 410 (33%) , 0.0001
Therapy
Beta-blockers 146 (17%) 166 (18%) 273 (22%) 0.007
ACE inhibitors 150 (17%) 198 (22%) 315 (35%) , 0.0001
Diuretic drugs 240 (28%) 309 (34%) 432 (35%) 0.001
Data presented are mean value 6 SD or number (%) of patients.
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variance. Discrete variables were analyzed using the chi-square
test; p , 0.05 was considered statistically significant.
Results
Indications. The use of dobutamine echocardiography in-
creased substantially from 1991 to 1995 (Table 1). The reasons
for performing dobutamine echocardiography rather than an
exercise test included inability to exercise because of claudica-
tion, orthopedic diseases, advanced age and other medical
conditions precluding adequate physical exercise, as well as
testing for the identification of viable myocardium. Figure 1
shows the evolution of the use of dobutamine echocardiogra-
phy from a test used for symptom evaluation to its use for risk
stratification.
Response to dobutamine stress. The hemodynamic re-
sponses to dobutamine stress are shown in Table 2. Over the
5-year period, the mean peak dose of dobutamine given
increased from 34.1 to 38.5 mg/kg per min, with a commensu-
rate increase in stress duration from 14 6 4 to 15 6 3 min.
Atropine was added to the protocol almost three times as often
in 1995 (39%) than in earlier years. This addition of atropine
led to a significantly higher mean peak heart rate (134 beats/
min) and percent of maximal heart rate attained (87%). From
15% to 20% of the tests showed evidence of ischemia.
Figure 2 examines the relation between diagnostic test
responses and the peak dose administered during the test. The
highest percentage of diagnostic tests was obtained using a
peak dose of 40 mg/kg per min. Of the 925 patients who had no
ischemia and were below the target heart rate at a dose of
40 mg/kg per min, 220 (mainly with contraindications to
atropine) underwent an additional increment of dobutamine
(to 50 mg/kg per min), and 98 (45%) finally attained their
target heart rate. Of the 935 patients who received atropine
because of a suboptimal heart rate response, the target heart
rate was achieved in 664 (71%). The mean total dose of
dobutamine administered as well as mean stress time were
significantly higher in those given atropine (17 6 2 vs. 14 6
3 min, 33.5 6 12.8 vs. 21.8 6 10.1 mg, respectively, p , 0.0001
for both).
Patients treated with beta-blockers achieved a significantly
lower peak heart rate (127 6 20 vs. 134 6 17 beats/min, p ,
0.0001) and percent of maximal predicted heart rate (82 6
13% vs. 87 6 11%, p , 0.0001) than those not treated with
beta-blockers, despite the more frequent administration of
atropine (57% vs. 25%, p , 0.0001). Patients with a rest heart
rate ,50 beats/min showed a similar trend, achieving target
heart rate in only 51% compared with 71% without bradycar-
dia at rest. Of 43 patients with a cardiac pacemaker, only 54%
achieved their target heart rate, and 35% of tests required
additional increments of dobutamine or atropine, or both.
Figure 1. Evolution of indications for dobutamine stress echocardiog-
raphy from 1991 to 1995. Solid bars 5 symptom evaluation; hatched
bars 5 risk stratification.






(n 5 1,239) p Value
Peak dobut dose (mg) 34 6 9 37 6 7 39 6 7 , 0.0001
Atropine 117 (13.5%) 308 (34%) 447 (39%) , 0.0001
Stress time (min) 14 6 4 15 6 3 15 6 3 , 0.0001
Rest HR (beats/min) 75 6 14 75 6 14 74 6 14 0.24
Rest SBP (mm Hg) 148 6 27 147 6 25 149 6 25 0.11
Peak HR (beats/min) 129 6 18 134 6 18 134 6 17 , 0.0001
Max predicted HR% (peak) 83 6 12 87 6 12 87 6 10 , 0.0001
Peak SBP (mm Hg) 146 6 35 148 6 36 149 6 25 0.07
Ischemia identified 158 (18%) 139 (15%) 247 (20%) 0.03
Data presented are mean value 6 SD or number (%) of patients. dobut 5 dobutamine; HR 5 heart-rate; SBP 5 systolic blood pressure.
Figure 2. Relation between diagnostic test responses and peak dobu-
tamine dose.
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End points of dobutamine stress. The indications for con-
cluding the test are shown in Figure 3. Side effects led to the
premature conclusion of the protocol in 13.8% of the initial
cohort, 7.0% of the patients studied in 1994 and 3.7% of those
studied in 1995 (Fig. 3). The higher threshold for terminating
the test because of side effects was not attended by a greater
frequency of serious arrhythmias (Table 3). Medical interven-
tion was required in 275 (9%) of all studies, including nitro-
glycerin (n 5 109 [3.6%]), beta-blockers (n 5 106 [3.5%]),
calcium channel blocking agents (n 5 35 [1.2%]) and saline for
hypotension (n 5 64 [2.1%]). Other drug therapy included the
use of atropine for vagal symptoms (five patients), lidocaine for
ventricular tachycardia, adenosine and digoxin for supraven-
tricular tachycardia, dopamine for hypotension and diazepam
for anxiety.
Angina occurred in ;25% of patients (n 5 748), and its
overall incidence did not differ to a meaningful degree over the
years. Patients with a history of myocardial infarction were
more likely to develop dobutamine-induced angina (29% vs.
24%, p 5 0.02), as were patients with a history of typical and
atypical chest pain (41% vs. 19%, p , 0.0001).
Serious complications. Major complications (i.e., death,
myocardial infarction, sustained ventricular tachycardia or
other conditions requiring inpatient observation) developed in
9 (0.3%) of 3,011 patients over 5 years. There were five cases
of sustained ventricular tachycardia and one myocardial infarc-
tion, but neither ventricular fibrillation nor death occurred.
Three additional patients required short-term inpatient obser-
vation for suspected myocardial infarction, supraventricular
tachycardia and hypotension, respectively.
The patient who had a myocardial infarction had an inferior
myocardial infarction (treated with stenting of the right coro-
nary artery) 1 month before dobutamine echocardiography.
The test was performed because she continued to experience
chest pain after intervention. Angina and inferior wall ischemia
were induced by stress, which completely resolved by 6 min
into recovery but recurred 15 min later. Coronary angiography
revealed thrombotic occlusion of the stent in the right coronary
artery. The patient admitted for severe ischemia had devel-
oped ST segment elevation, progressive chest discomfort and
severe left ventricular dysfunction with peak infusion of
50 mg/kg per min and 1.0 mg atropine. This was thought to be
consistent with severe three-vessel disease, but cardiac cathe-
terization revealed completely normal coronary arteries with-
out evidence of atherosclerosis. The event was thought to be
due either to diffuse coronary artery spasm or to microvascular
disease.
Of the patients with serious arrhythmias, one was observed
in the hospital after sustained but asymptomatic supraventric-
ular tachycardia (up to 175 beats/min) after peak infusion of
40 mg/kg per min of dobutamine and 0.8 mg of atropine. This
arrhythmia persisted for 20 min in recovery before spontane-
ously converting back to sinus rhythm. Sustained ventricular
tachycardia was controlled by intravenous lidocaine in one
patient, and another required cardioversion; the other three
recovered without medical intervention. No arrhythmic event
was associated with signs of induced ischemia. Four patients
had a history of myocardial infarction, one of repeated rapid
supraventricular tachycardia.
Minor complications. Hypotension. The most frequent mi-
nor complication was hypotension, which occurred in 7% of
patients (n 5 198) and provoked test termination in 3.5% in
the initial years and in 1.1% in the final year of the study. All
patients completely recovered, usually after discontinuation of
dobutamine; some patients required administration of fluids.
These patients were older (69 6 10 vs. 65 6 12 years, p ,
0.0002) and had a lower rest systolic blood pressure (139 6 21
vs. 149 6 26 mm Hg, p , 0.0001) and a slightly higher rest
heart rate (78 6 14 vs. 74 6 14 beats/min, p 5 0.001) than the
rest of the group. The hypotensive response was less common
in patients with beta-blocker therapy and was unrelated to
ACE inhibitor or calcium antagonist therapy or the presence
of hypertension, diabetes mellitus or preceding angina.
Hypertension. Hypertension (systolic blood pressure
.220 mm Hg) occurred in 82 patients, 24 of whom had the test
terminated for this reason. Hypertension settled spontaneously
after conclusion of the protocol in most patients, but six
required therapy with a beta-blocker or calcium antagonist, or
both. A hypertensive blood pressure response correlated with
a history of hypertension (54% vs. 40% in those without
exaggerated response, p , 0.02) and beta-blocker therapy
(45% vs. 19%, p , 0.0001). In the group with a hypertensive
response, rest and peak heart rates were lower (68 6 12 vs.
75 6 14 beats/min and 119 6 28 vs. 133 6 17 beats/min,
Figure 3. Reasons for test termination in 3,011 dobutamine stress
echocardiograms obtained from 1991 to 1995. Solid areas 5 side
effects; open areas 5 ischemia; hatched areas 5 end of protocol.
Table 3. Major Arrhythmias in 3,011 Dobutamine Echocardiograms
Between 1991 and 1995
1991–1993 1994 1995 p Value
VT 17 (2%) 28 (3%) 28 (2%) 0.26
Sustained VT 3 (0.3%) 1 (0.1%) 1 (0.1%) 0.30
AF 5 (0.6%) 13 (1.4%) 16 (1.3%) 0.18
Data presented are number (%) of patients. AF 5 atrial fibrillation; VT 5
ventricular tachycardia.
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respectively, both p , 0.0001), and rest systolic blood pressure
was higher (171 6 28 vs. 148 6 26 mm Hg, p , 0.0001) than
those without this complication.
Arrhythmias. Arrhythmias developed in 438 patients
(15%), most frequently minor ventricular ectopic beats (n 5
242). Mild atrial arrhythmias (including junctional rhythm and
premature atrial contractions .10/min) and Wenckebach
block occurred in 32 patients. The test was stopped because of
these complications in only eight patients. Ventricular tachy-
cardia occurred in 73 patients, leading to test termination in
18. The development of ventricular tachycardia did not corre-
late significantly with the total dose of dobutamine (20 vs.
26 mg in patients without ventricular tachycardia) or adminis-
tration of atropine (19% vs. 31%) or with chest pain history
(19% vs. 25%), beta-blocker therapy (15% vs. 20%), diuretic
drug use (21% vs. 28%), diabetes mellitus (23% vs. 19%),
hypertension (33% vs. 41%), age or body weight. However,
whereas 45 patients with ventricular tachycardia also devel-
oped angina or ECG evidence of ischemia during dobutamine
echocardiography, only 16 showed worsening wall motion
scores (21% vs. 18% in patients without ventricular tachycar-
dia, p 5 0.39). Sustained supraventricular arrhythmias oc-
curred in 85 patients (2.8%) (supraventricular tachycardia in
53, atrial fibrillation in 32) and led to early termination of the
test in 18. Arrhythmias were no more frequent in 165 patients
who were evaluated for at least moderate left ventricular
dysfunction than in patients studied for other reasons (4.9% vs.
5.3%, p 5 0.94), although the former less often achieved their
target heart rate (65.5% vs. 73.2%, p , 0.05).
Noncardiac side effects. Significant noncardiac side effects
occurred in 84 patients (2.8%), the most common of which
were nausea (n 5 54) and shortness of breath (n 5 19). Three
patients experienced severe headache (including one with
typical migraine attack) and anxiety; other possible neurologic
sequellae included myoclonic spasms, painful burning in the
ears and transient double vision (each occurring in one pa-
tient). One patient developed a transient confusional state
after being stressed with dobutamine without atropine.
Discussion
The use of dobutamine echocardiography for the evalua-
tion of known or suspected coronary artery disease in patients
who cannot exercise adequately has expanded rapidly. The
test, which is relatively inexpensive compared with competing
technologies, is versatile and usually provides high quality
images due to the absence of patient movement and limited
respiratory interference. A number of studies have docu-
mented favorable sensitivity and specificity, especially with
high dose protocols and supplemental administration of atro-
pine (14,15,21). At the same time, with more aggressive
protocols and inclusion of high risk patients with a potentially
greater risk for complications, concerns have been raised about
the safety of dobutamine echocardiography (18). Several stud-
ies have addressed this issue in the past, but these have
involved less aggressive stress protocols and smaller numbers
of patients from individual centers (16,17,22) or a multicentric
approach, which may pose problems with respect to inhomo-
geneity of data collection and variations in patient selection.
Present study. The present single-center study of .3,000
consecutive examinations documents the safety and side effects
of dobutamine echocardiography in relation to changes in the
indications and protocol as the test has evolved over 5 years.
The test was well tolerated in most patients who underwent
dobutamine echocardiography at our institution from 1991
until 1995; major complications occurred in nine patients but
no mortality. With the trend toward high dose protocols and
administration of atropine in more than a third of the studies,
the percentage of diagnostic tests (positive for ischemia or
negative with a maximal heart rate response) increased from
59% to 80%. At the same time, fewer tests were stopped
because of side effects (4% vs. 14%), reflecting increasing
confidence in the safety of the dobutamine echocardiography
protocol. Reduction of systolic blood pressure in the course of
the test is now more readily accepted by the monitoring
physician, and left ventricular outflow obstruction, which led to
termination of the test in .5% of patients in 1993, was the end
point in only 0.1% of studies in 1995. Similar trends can be
observed with respect to the development of chest pain during
dobutamine echocardiography; recently, we have terminated
the test only for severe chest pain or if additional markers of
ischemia were present. Continuing with the test despite the
presence of angina permits definition of the the full extent of
ischemia.
Complications. Neither death nor ventricular fibrillation
occurred in our experience. The occurrence of myocardial
infarction after dobutamine echocardiography in one patient
supports the use of caution in severely symptomatic patients,
even if the symptoms appear atypical. The patient with an
apparently impending infarction after dobutamine echocardi-
ography but without evidence of coronary disease at angiogra-
phy may reflect a hyperadrenergic response or coronary spasm
provoked by dobutamine (23). Serious complications from
dobutamine echocardiography occurred in 1 of 335 tests, in
agreement with previous, smaller studies (16,17,22), and some-
what less than the 1 in 210 incidence reported by Picano et al.
(18). The main source of discrepancy was the absence of
atropine induced psychosis during dobutamine echocardiogra-
phy in our experience (indeed, the only patient who experi-
enced an altered mental status with confusion and disorienta-
tion had not received any atropine). The frequency of serious
events in all reported dobutamine studies is comparable to that
reported for exercise testing in patients with coronary artery
disease (24).
As reported by other investigators, the most commonly
encountered adverse effects were arrhythmias and hypoten-
sion. The majority of arrhythmias were ventricular ectopic
activity; more serious rhythm disorders (supraventricular
tachycardia, ventricular tachycardia, atrial fibrillation) oc-
curred in 107 patients (3.6%), similar to the experience of
Mertes et al. (16) (4.3%) and Poldermans et al. (22) (3.6%).
Atrial fibrillation and supraventricular tachycardia were well
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tolerated by the patients and responded promptly to termina-
tion of the test; only six patients required medical intervention.
Of five patients with ventricular tachycardia, hemodynamic
variables remained stable in four, and only one required an
electric countershock because of hemodynamic compromise.
No clinical predictors of ventricular tachycardia could be
identified, and its occurrence was not correlated with higher
doses of dobutamine or administration of atropine, similar to
the experience of McNeill et al. (14) and Mertes et al. (16).
Patients with left ventricular dysfunction and those with a
pacemaker had no higher risk of developing ventricular tachy-
cardia than patients tested for other reasons.
Reduction of systolic blood pressure, which was the second
most common side effect, was also well tolerated and readily
reversed after test termination and intravenous fluids, if re-
quired. In the course of the study period, this side effect was
less commonly a reason for stopping the test. Contrary to
previous reports by Tanimoto et al. (25), we did not find a
positive correlation between therapy with ACE inhibitors and
a decrease in systolic blood pressure, or a correlation with
elevated baseline systolic blood pressure, as described by
Lieberman et al. (26). Administration of atropine during
dobutamine echocardiography was inversely related to a de-
crease in systolic blood pressure, most likely by its vagal
suppressant effect, supported by the finding that no patient
with severe vagal reaction had received atropine during dobu-
tamine echocardiography.
Adequacy of stress. The use of atropine has been shown
(14,15) to increase the sensitivity of dobutamine echocardiog-
raphy, especially in patients receiving treatment with beta-
blockers. However, administration of atropine in the late
stages of dobutamine echocardiography considerably prolongs
the duration of the test, leading to infusion of a higher total
dose of dobutamine. The use of greater doses of dobutamine,
with and without atropine, has led to a higher percentage of
diagnostic tests without increasing the risk of severe side
effects.
Conclusions. The results of this single-center study of
3,011 consecutive studies confirm that dobutamine echocardi-
ography is a safe test for the purposes of diagnosis and risk
stratification in patients with known or suspected coronary
artery disease. This has remained true despite the trend toward
more aggressive protocols and inclusion of high risk patients.
Further studies are necessary to investigate ways of optimizing
the dobutamine echocardiographic protocol according to the
needs of selected patient groups, such as those with diabetes
mellitus or taking beta-blocker therapy.
We acknowledge the tireless work of the sonographers, fellows and staff of the
Echocardiography Laboratory of the Cleveland Clinic Foundation.
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